CD8+ Cancer Research Results

CD8+, CD8+ T cell: Click to Expand ⟱
Source:
Type: T cell
CD8+ T cells are "end effectors" of cancer immunity.
Cytotoxic T cells expressing cell-surface CD8 are the most powerful effectors in the anticancer immune response and form the backbone of current successful cancer immunotherapies.
CD8+ T cells, also known as cytotoxic T lymphocytes (CTLs), play a crucial role in the immune response against cancer. They are responsible for identifying and killing cancer cells that present abnormal antigens, which can arise from mutations or viral infections.
BC, Breast Cancer: Click to Expand ⟱
Breast Cancer
Scientific Papers found: Click to Expand⟱
6030- CGA,    Chlorogenic acid induces apoptosis, inhibits metastasis and improves antitumor immunity in breast cancer via the NF‑κB signaling pathway
- vitro+vivo, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-453 - in-vitro, Nor, MCF10
NF-kB↓, AntiTum↑, tumCV↓, TumCP↓, Apoptosis↑, TumCMig↓, TumCI↓, EMT↓, TumCG↓, OS↑, TumMeta↓, CD4+↑, CD8+↑, Imm↑,
1859- dietFMD,  Chemo,    Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity
- in-vitro, BC, 4T1 - in-vivo, Melanoma, B16-BL6
CLP↑, CD8+↑, TumCG↓, HO-1↓, TILs↑,
5604- NaHCO3,    Mitochondrial metabolic reprogramming of macrophages and T cells enhances CD47 antibody-engineered oncolytic virus antitumor immunity
- vitro+vivo, Melanoma, B16-BL6 - in-vitro, BC, 4T1
eff↑, eff↑, TumMeta↓, pH↑, CaMKII ↑, CREB↑, PGC-1α↑, AntiTum↑, Imm↑, CD8+↑, TAMS↑,
3092- RES,    Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action
- Review, BC, MDA-MB-231 - Review, BC, MCF-7
TumCP↓, tumCV↓, TumCI↓, TumMeta↓, *antiOx↑, *cardioP↑, *Inflam↓, *neuroP↑, *Keap1↓, *NRF2↑, *ROS↓, p62↓, IL1β↓, CRP↓, VEGF↓, Bcl-2↓, MMP2↓, MMP9↓, FOXO4↓, POLD1↓, CK2↓, MMP↓, ROS↑, Apoptosis↑, TumCCA↑, Beclin-1↓, Ki-67↓, ATP↓, GlutMet↓, PFK↓, TGF-β↓, SMAD2↓, SMAD3↓, Vim?, Snail↓, Slug↓, E-cadherin↑, EMT↓, Zeb1↓, Fibronectin↓, IGF-1↓, PI3K↓, Akt↓, HO-1↑, eff↑, PD-1↓, CD8+↑, Th1 response↑, CSCs↓, RadioS↑, SIRT1↑, Hif1a↓, mTOR↓,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

HO-1↓, 1,   HO-1↑, 1,   ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   MMP↓, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis ⓘ

CREB↑, 1,   GlutMet↓, 1,   PFK↓, 1,   POLD1↓, 1,   SIRT1↑, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 2,   Bcl-2↓, 1,   CK2↓, 1,  

Kinase & Signal Transduction ⓘ

CaMKII ↑, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 2,  

Autophagy & Lysosomes ⓘ

Beclin-1↓, 1,   p62↓, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 1,   EMT↓, 2,   FOXO4↓, 1,   IGF-1↓, 1,   mTOR↓, 1,   PI3K↓, 1,   TumCG↓, 2,  

Migration ⓘ

E-cadherin↑, 1,   Fibronectin↓, 1,   Ki-67↓, 1,   MMP2↓, 1,   MMP9↓, 1,   Slug↓, 1,   SMAD2↓, 1,   SMAD3↓, 1,   Snail↓, 1,   TGF-β↓, 1,   TumCI↓, 2,   TumCMig↓, 1,   TumCP↓, 2,   TumMeta↓, 3,   Vim?, 1,   Zeb1↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 1,   TAMS↑, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

CD4+↑, 1,   CLP↑, 1,   CRP↓, 1,   IL1β↓, 1,   Imm↑, 2,   NF-kB↓, 1,   PD-1↓, 1,   Th1 response↑, 1,   TILs↑, 1,  

Cellular Microenvironment ⓘ

pH↑, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 3,   RadioS↑, 1,  

Clinical Biomarkers ⓘ

CRP↓, 1,   Ki-67↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 2,   OS↑, 1,  

Infection & Microbiome ⓘ

CD8+↑, 4,  
Total Targets: 63

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Keap1↓, 1,   NRF2↑, 1,   ROS↓, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   neuroP↑, 1,  
Total Targets: 7

Scientific Paper Hit Count for: CD8+, CD8+ T cell
1 Chlorogenic acid
1 diet FMD Fasting Mimicking Diet
1 Chemotherapy
1 Bicarbonate(Sodium)
1 Resveratrol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:4  Cells:%  prod#:%  Target#:344  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page